Meeting
2024 ASCO Annual Meeting
Preliminary results of a phase 1 study of Decoy20, an intravenous, killed, multiple immune receptor agonist bacterial product in patients with advanced solid tumors.
Authors
Roger J. Waltzman
Indaptus, New York, NY
Roger J. Waltzman , Jeffery A. Nieves , Diana L. Hanna , Angela Tatiana Alistar , Mohammed Najeeb Al Hallak , Ira Seth Winer , Manali A. Bhave , Jacob Stephen Thomas , Anthony B. El-Khoueiry , Michael J. Newman
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
New Targets and New Technologies (IO)
Clinical Trial Registration Number
NCT05651022
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 2583)
DOI
10.1200/JCO.2024.42.16_suppl.2583
Abstract #
2583
Poster Bd #
62
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Phase I study of MP0317, a FAP-dependent DARPin, for tumor-localized CD40 activation in patients with advanced solid tumors.
First Author: Carlos A. Gomez-Roca
Poster
2023 ASCO Annual Meeting
A phase Ib study of endogenous T cell therapy using SLC45A2-specific CD8 T cells for patients with metastatic uveal melanoma.
First Author: Suzanne Phillips
Poster
2022 ASCO Annual Meeting
First-in-human dose escalation and expansion study of MT-6402, a novel engineered toxin body (ETB) targeting PD-L1, in patients with PD-L1 expressing relapsed/refractory advanced solid tumors: Interim data.
First Author: Eugene R Ahn
Poster
2021 ASCO Annual Meeting
Safety, pharmacokinetics, efficacy, and preliminary biomarker data of first-in-class BI 765063, a selective SIRPα inhibitor: Results of monotherapy dose escalation in phase 1 study in patients with advanced solid tumors.
First Author: Stéphane Champiat